INJECTIBLE Hypoglycemic Drugs GLP-1 Analogs Exenatide ER Trade Names: Byetta (daily) Bydureon (weekly - extended release) Generic (Nov 2024) Drug Class: DPP-IV resistant Incretin (GLP-1 like) Mimetic Mechanism of Action: a synthetic analog of glucagon-like-polypeptide 1 (GLP-1) that is resistant to breakdown by DPP-IV
Higbie V, LaPelusa MB, Shah P, Childress M, Gasco A, An A, Bent AH, Kee BK, Kopetz S , Le P, Morris VK, Pant S, Parseghian C, Shen JP, Wolff RA, Overman MJ
Overweight individuals are those with a body mass index (BMI) greater than or equal to 25, while obesity is defined as a BMI of 30 or higher [4]
BPC-157 appears to directly enhance the integrity of tight junctions the protein complexes that seal the space between epithelial cells
P-21 What It Is: A small molecule mimetic of ciliary neurotrophic factor (CNTF) designed for neurogenesis and neuroprotection
Cardiovascular events and PsD A meta-analysis of 11 studies reported a 43% increased risk of CV diseases in PsA patients compared to the general population, with elevated risks of myocardial infarction (68%), cerebrovascular disease (22%), and heart failure (31%) [64]
